Background:

Suplatast Tosilate (IPD 1151T) is a Th2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production. IC50 value:Target: Th2 cytokine inhibitorSuplatast Tosilate acts as an immunoregulator that suppresses IgE production, eosinophil infiltration and histamine release. Suplatast Tosilate(IPD 1151T) exhibits antiasthmatic, anti-inflammatory and antifibrotic activity in vivo and is orally active.

参考文献:
[1]. Bito T, Kabashima R, Sugita K, Tokura Y.Angiolymphoid hyperplasia with eosinophilia on the leg successfully treated with T-helper cell 2 cytokine inhibitor suplatast tosilate.J Dermatol. 2011 Mar;38(3):300-2. doi: 10.1111/j.1346-8138.2010.00990.x.
[2]. Shimizu S, Hattori R, Majima Y, Shimizu T.Th2 cytokine inhibitor suplatast tosilate inhibits antigen-induced mucus hypersecretion in the nasal epithelium of sensitized rats.Ann Otol Rhinol Laryngol. 2009 Jan;118(1):67-72.
[3]. Furonaka M, Hattori N, Tanimoto T, Senoo T, Ishikawa N, Fujitaka K, Haruta Y, Yokoyama A, Kohno N.Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice.J Pharmacol Exp Ther. 2009 Jan;328(1):55-61.
[4]. Kurokawa et al (2001) Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo. Mediators Inflamm. 10 333.
[5]. Furonaka et al (2009) Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice. J.Pharmacol.Exp.Ther. 328 55.